Association between diabetes duration and hyperuricemia: Korea National Health and Nutrition Examination Survey 2016 to 2021

Article information

Korean J Intern Med. 2026;41(1):143-151

Publication date (electronic) : 2026 January 1

doi : https://doi.org/10.3904/kjim.2024.436

Kyuho Kim ¹^,^*, Kyungdo Han ²^,^*, In Young Kim ³, Kyuna Lee ², Yu-Bae Ahn ¹, Seung-Hyun Ko ¹, Jae-Seung Yun ¹

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea

³MediRama Inc., Seoul, Korea

Correspondence to: Jae-Seung Yun, M.D., Ph.D. Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea, Tel: +82-31-249-8059, Fax: +82-31-247-8058, E-mail: dryun@catholic.ac.kr, https://orcid.org/0000-0001-5949-1826

These authors contributed equally to this manuscript.

Received 2024 December 24; Revised 2025 May 23; Accepted 2025 June 9.

Abstract

Background/Aims

We examined the association between diabetes duration and hyperuricemia in Korean subjects based on data from the Korea National Health and Nutrition Examination Survey (KNHANES).

Methods

This cross-sectional study included 4,575 subjects aged 30 years and older with type 2 diabetes mellitus based on data from the KNHANES from 2016 to 2021. Hyperuricemia was defined as a serum uric acid level ≥ 7.0 mg/dL. Univariable and multivariable logistic regression models were used calculate adjusted odds ratios (ORs) and their 95% confidence intervals (CIs).

Results

The mean age of subjects was 61.0 years, 56.5% were male, and the mean body mass index (BMI) was 25.6 kg/m². Compared to those with diabetes duration 5 to < 10 years, those with shorter or longer diabetes duration had higher serum uric acid levels and higher prevalence of hyperuricemia. In multivariable logistic regression models, a U-shaped association between diabetes duration and hyperuricemia was observed after adjusting for age, sex, income, smoking status, alcohol consumption, regular exercise, and presence of hypertension, dyslipidemia, or chronic kidney disease. Compared to those with new-onset diabetes mellitus, the adjusted OR (95% CI) for hyperuricemia was 0.55 (0.38–0.82) in those with diabetes duration 5 to < 10 years. The results were consistent in subgroup analysis according to age, sex, BMI, and chronic kidney disease.

Conclusions

The U-shaped association between diabetes duration and hyperuricemia was observed in a representative sample of Korean adults.

Keywords: Diabetes mellitus; Hyperuricemia; Cross sectional analysis

Graphical abstract

INTRODUCTION

Diabetes mellitus is one of the most common metabolic diseases and is characterized by insulin resistance and beta cell dysfunction [1]. The prevalence of diabetes in Korea was estimated to be 13.9% in 2020 [2]. The global prevalence of diabetes in 2021 was estimated to be 10.5% (536 million) and is predicted to increase to 12.2% (783 million) in 2045 [3]. The diabetes duration is known to be significantly associated with the risk of metabolic syndrome [4].

Serum uric acid is the metabolic end-product of the purine nucleotides. Hyperuricemia or elevated serum uric acid level results from overproduction or decreased renal excretion of serum uric acid [5]. According to the data from the Korea National Health and Nutrition Examination Survey (KNHANES), the prevalence of hyperuricemia in Korea was estimated to be 11.4% in 2016 [6]. According to the data from the National Health and Nutrition Examination Survey, the prevalence of hyperuricemia in the United States was about 20% between 2015 to 2016 [7]. Hyperuricemia is associated with multiple components of metabolic syndrome such as hyperglycemia, obesity, dyslipidemia, and hypertension [8]. In addition, several studies have shown that hyperuricemia is a risk factor for cardiovascular diseases [9–11].

Several studies have examined the association between diabetes and hyperuricemia. Some reported a positive association between diabetes and hyperuricemia [12–14], but other reported no association [15], or an inverse association [16,17]. However, the association between diabetes duration and hyperuricemia has not been well-studied.

Therefore, we aimed to investigate the association between diabetes duration and hyperuricemia in subjects with type 2 diabetes mellitus (T2DM) based on data from the KNHANES from 2016 to 2021.

METHODS

Study population

We used the KNHANES database, a population-based, cross-sectional survey consisting of health examination, health interview, and nutrition survey data. The KNHANES population comprises non-institutionalized Korean citizens residing in Korea, and the sampling follows a multi-stage clustered probability design [18]. In the present study, data from the 7th (2016–2018) and 8th phases (2019–2021) of the KNHANES were used. Of the 46,828 subjects in the 2016–2021 KNHANES, we excluded those aged < 30 years (n = 13,477), those without diabetes (n = 28,293), and those with missing data (n = 483). The remaining 4,575 subjects were included in the study (Fig. 1).

Figure 1

A flowchart of the study population enrollment. KNHANES, Korea National Health and Nutrition Examination Survey.

This study was approved by the Institutional Review Board of The Catholic University of Korea, St. Vincent’s Hospital (approval number: VC23ZISI0201). The requirement for informed consent was waived. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Collection of data

Healthcare professionals at the survey sites measured anthropometric indices, body mass index (BMI), waist circumference, and blood pressure (BP). Information about medical conditions, smoking status, alcohol consumption, and exercise was obtained through a face-to-face interview and self-administered survey questionnaire. Laboratory tests including a lipid profile and fasting blood glucose, HbA1c, blood urea nitrogen, creatinine, and uric acid levels were performed [19].

Variables

Smoking status was categorized into non-smokers, ex-smokers, and current smokers. Alcohol consumption was categorized into non-drinker, mild drinker (< 30 g/day), and heavy drinker (≥ 30 g/day). Regular exercise was defined as > 150 minutes of moderate-intensity or > 75 minutes of vigorous-intensity physical activity, or some equivalent combination of moderate-intensity and vigorous-intensity aerobic physical activity, per week [20]. Low income (Q1) was defined as the lowest 25% income bracket of the total population based on monthly income.

T2DM was defined as fasting glucose level ≥ 126 mg/dL, previous history of T2DM, or use of antidiabetic medications or insulin. Diabetes duration was classified into five groups: new-onset diabetes, diabetes duration < 5 years, diabetes duration 5 to < 10 years, diabetes duration 10 to < 15 years, and diabetes duration ≥ 15 years. Hyperuricemia was defined as a serum uric acid level ≥ 7.0 mg/dL based on previous studies [21–23]. Hypertension was defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg, a previous history of hypertension, or use of antihypertensive medications. Dyslipidemia was defined as a total cholesterol level ≥ 240 mg/dL or use of antidyslipidemic medications. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² as calculated by the Modification of Diet in Renal Disease formula. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as follows: fasting insulin (μIU/mL) × fasting glucose (mg/dL)/405.

Statistical analysis

Baseline characteristics of the participants are presented as the mean ± standard deviation or number with percentage (%). Baseline characteristics were compared between groups using the chi-square test for categorical variables and ANOVA for continuous variables. Multivariable logistic regression analysis was performed to assess the association between diabetes duration and hyperuricemia. The odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unadjusted and multivariable adjusted models. Model 1 was non-adjusted. Model 2 was adjusted for age and sex. Model 3 was adjusted for Model 2 factors plus income (Q1), smoking status, alcohol consumption, and regular exercise. Model 4 was adjusted for Model 3 factors plus hypertension, dyslipidemia, and CKD. Subgroup analyses were conducted according to age, sex, BMI, and CKD. All analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC, USA). A two-sided p value < 0.05 was considered statistically significant without adjustment for multiple comparisons.

RESULTS

Baseline characteristics

The mean age of subjects was 61.0 ± 4.6 years, their mean BMI was 25.6 ± 0.8 kg/m², and 56.5% were male. Subjects with longer diabetes duration showed a decreasing trend in BMI, waist circumference, diastolic BP, insulin levels, HOMA-IR, total cholesterol, and LDL cholesterol and an increasing trend in creatinine levels, compared to those with new-onset diabetes. The prevalence of low income (Q1), hypertension, and CKD was higher among subjects with longer diabetes duration. The prevalence of hyperuricemia was 10% for all subjects. Compared to those with diabetes duration 5 to < 10 years, those with shorter or longer durations had higher serum uric acid levels and higher prevalence of hyperuricemia (Table 1).

Table 1

Baseline characteristics of the study population

Association between diabetes duration and hyperuricemia

The prevalence of hyperuricemia was 13.4%, 8.0%, 7.1%, 8.0%, and 10.9% in those with new-onset diabetes, diabetes duration < 5 years, diabetes duration 5 to < 10 years, diabetes duration 10 to < 15 years, and diabetes duration ≥ 15 years, respectively. In the non-adjusted model, diabetes duration < 5 years, diabetes duration 5 to < 10 years, and diabetes duration 10 to < 15 years were associated with lower prevalence of hyperuricemia. After multivariable adjustment, a U-shaped association between diabetes duration and hyperuricemia was observed (OR 0.56, 95% CI 0.41–0.75 for those with diabetes duration < 5 years; OR 0.55, 95% CI 0.38–0.82 for those with diabetes duration 5 to < 10 years; OR 0.58, 95% CI 0.37–0.91 for those with diabetes duration 10 to < 15 years; and OR 0.89, 95% CI 0.61–1.29 for those with diabetes duration ≥ 15 years) (Table 2 and Fig. 2).

Table 2

Association between diabetes duration and hyperuricemia

Figure 2

Association between diabetes duration and hyperuricemia. ORs with 95% CIs are presented as dot and whisker plots after adjusting for covariates: age, sex, income (Q1), smoking status, alcohol consumption, regular exercise, hypertension, dyslipidemia, and chronic kidney disease. OR, odds ratio; CI, confidence interval.

Subgroup analyses according to age, sex, BMI, and CKD

The relationship between diabetes duration and hyperuricemia did not demonstrate significant interactions with age, sex, BMI, or CKD, instead showing a consistent OR trend across these factors (Table 3).

Table 3

Association between diabetes duration and hyperuricemia stratified by age, sex, BMI, and CKD

DISCUSSION

In this study, we investigated the association between diabetes duration and hyperuricemia. These are the main findings. First, the prevalence of hyperuricemia was 10% in Korean adults with T2DM. Second, the U-shaped association between diabetes duration and hyperuricemia was observed, particularly in those with a diabetes duration 5 to < 10 years who showed a 45% decreased prevalence of hyperuricemia compared to those with new-onset diabetes. Third, this U-shaped association was consistently observed in subgroup analyses according to sex, age, BMI, and CKD.

In this study, hyperuricemia was defined as a serum uric acid level ≥ 7.0 mg/dL, and the prevalence of hyperuricemia in subjects with T2DM was 10%. A previous study using data from the 2016 KNHANES reported a prevalence of hyperuricemia of 13.3% in those with T2DM when hyperuricemia was defined as a serum uric acid level ≥ 7.0 mg/dL in male and ≥ 6.0 mg/dL in female [24]. Differences in the definition of hyperuricemia and duration of data collection may have caused the discrepancies in prevalence between studies.

There have been several studies that demonstrated associations between diabetes and hyperuricemia, some positive associations [12,14] and some negative [16,17]. However, the association between diabetes duration and hyperuricemia has not been well-studied. In this study, we found the U-shaped association between diabetes duration and hyperuricemia. A plausible explanation for this finding is that as diabetes duration increased, higher glucose inhibited uric acid reabsorption in the proximal tubule of the kidney [25,26]. Alternatively, metformin, the mainstay of T2DM treatment, may reduce serum uric acid levels [27,28]. Metformin activates 5’-adenosine monophosphate-activated protein kinase, inhibiting gluconeogenesis [29]. This inhibition leads to reduced fatty acid and uric acid synthesis, decreasing serum uric acid levels [30]. We found no significantly decreased resence of hyperuricemia in those with diabetes duration ≥ 15 years. Considering results from a previous study in which eGFR ≥ 60 mL/min/1.73 m² was negatively associated with hyperuricemia [31], a higher prevalence of CKD in those with diabetes duration ≥ 15 years in this study may have affected the results. However, even after multivariable adjustment including CKD, there was no significant decreased prevalence of hyperuricemia in those with diabetes duration ≥ 15 years. Alternatively, by following the Korean Diabetes Association consensus statement that recommends discontinuation of metformin in subjects with eGFR < 30 mL/min/1.73 m² [32], the proportion of metformin users may be decreased in those with diabetes duration ≥ 15 years. Exclusion of the uric acid lowering effect of metformin in this group may have affected the results.

In this study, we found no significant interaction of BMI in the association between diabetes duration and hyperuricemia. However, considering previous studies that have demonstrated an association between HOMA-IR and hyperuricemia [33,34], as well as the trend of decreasing HOMA- IR with increasing diabetes duration observed in our study, we cannot exclude the potential confounding effect of insulin resistance on the association between diabetes duration and hyperuricemia.

The present study has several limitations. First, because this was conducted as a cross-sectional study, a causal relationship could not be established. Second, we were unable to adjust for confounding factors that could influence serum uric acid levels, such as underlying diseases, insulin resistance, medications, or dietary intake. Third, the findings cannot be generalized to other races or ethnicities. However, despite these limitations, this study is the first to evaluate the prevalence of hyperuricemia according to diabetes duration in a representative sample of Korean adults. In addition, considering that old age, male sex, higher BMI, and renal dysfunction can increase serum uric acid levels [35–39], subgroup analyses were conducted according to age, sex, BMI, and CKD.

In conclusion, the U-shaped association was found between diabetes duration and hyperuricemia; in particular, those with diabetes duration 5 to < 10 years showed 45% decreased prevalence of hyperuricemia. This association was consistently observed regardless of age, sex, BMI, and CKD. Further studies that evaluate additional variables such as underlying diseases, insulin resistance, medications, or dietary intake are needed.

KEY MESSAGE

1. The prevalence of hyperuricemia was 10% in Korean adults with T2DM.

2. The U-shaped association between diabetes duration and hyperuricemia was observed.

Notes

CRedit authorship contributions

Kyuho Kim: conceptualization, methodology, investigation, data curation, formal analysis, validation, writing - original draft, writing - review & editing, visualization; Kyungdo Han: conceptualization, methodology, resources, investigation, data curation, formal analysis, validation, writing - original draft, writing - review & editing, visualization; In Young Kim: methodology, resources, investigation, data curation, formal analysis, validation; Kyuna Lee: methodology, resources, investigation, data curation, formal analysis, validation, visualization; Yu- Bae Ahn: methodology, resources, investigation, data curation, formal analysis, validation; Seung-Hyun Ko: methodology, resources, investigation, data curation, formal analysis, validation; Jae-Seung Yun: conceptualization, methodology, resources, investigation, formal analysis, validation, writing - original draft, writing - review & editing, supervision, project administration

Conflicts of interest

The authors disclose no conflicts.

Funding

None

Data availability

Data cannot be shared publicly due to the violation of patient privacy and the absence of informed consent for data sharing.

References

1. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019.

2. Ha KH, Lee KA, Han KD, Moon MK, Kim DJ. Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes. Korean J Intern Med 2023;38:93–100.

3. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119.

4. Sharma K, Poudyal S, Subba HK, Khatiwada S. Metabolic syndrome and life style factors among diabetes patients attending in a teaching hospital, Chitwan. PLoS One 2023;18:e0286139.

5. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 2012;4:12.

6. Park J, Son M, Lee SW, Chung WT, Lee SY. Association between oral health and hyperuricemia in Korean adults: Korea National Health and Nutrition Examination Survey 2016–2019. Korean J Intern Med 2024;39:1001–1010.

7. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol 2019;71:991–999.

8. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120:442–447.

9. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170–180.

10. Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep 2016;6:19520.

11. Chang CC, Wu CH, Liu LK, et al. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: the Taiwan I-Lan Longitudinal Aging Study. Sci Rep 2018;8:5234.

12. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008;31:361–362.

13. Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care 2009;32:1272–1273.

14. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737–1742.

15. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001;19:1209–1215.

16. Oda E, Kawai R, Sukumaran V, Watanabe K. Uric acid is positively associated with metabolic syndrome but negatively associated with diabetes in Japanese men. Intern Med 2009;48:1785–1791.

17. Nan H, Dong Y, Gao W, Tuomilehto J, Qiao Q. Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract 2007;76:68–74.

18. Kweon S, Kim Y, Jang MJ, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol 2014;43:69–77.

19. Kim Y. The Korea National Health and Nutrition Examination Survey (KNHANES): current status and challenges. Epidemiol Health 2014;36:e2014002.

20. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 2020;54:1451–1462.

21. Kuwabara M, Kuwabara R, Niwa K, et al. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in Japanese and American subjects. Nutrients 2018;10:1011.

22. Koo BS, Jeong HJ, Son CN, et al. Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a Korean general population of 172,970. Korean J Intern Med 2021;36(Suppl 1):S264–S272.

23. Hisatome I, Ichida K, Mineo I, et al. Japanese Society of Gout and Uric & Nucleic Acids 2019 guidelines for management of hyperuricemia and gout 3rd edition. Gout Uric Nucleic Acids 2020;44:sp-1–sp-40.

24. Jeong H, Moon JE, Jeon CH. Hyperuricemia is associated with an increased prevalence of metabolic syndrome in a general population and a decreased prevalence of diabetes in men. J Rheum Dis 2020;27:247–260.

25. Herman JB, Medalie JH, Goldbourt U. Diabetes, prediabetes and uricaemia. Diabetologia 1976;12:47–52.

26. Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986;62:1001–1006.

27. Dai H, Hou T, Wang Q, et al. The effect of metformin on urate metabolism: findings from observational and Mendelian randomization analyses. Diabetes Obes Metab 2024;26:242–250.

28. Barskova VG, Eliseev MS, Kudaeva FM, et al. Effect of metformin on the clinical course of gout and insulin resistance. Klin Med (Mosk) 2009;87:41–46. Russian.

29. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60:1577–1585.

30. Onyango AN. Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae. Heliyon 2022;8:e12294.

31. Sun S, Chen L, Chen D, et al. Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study. Ther Adv Endocrinol Metab 2023;14:20420188231198620.

32. Hur KY, Kim MK, Ko SH, Han M, Lee DW, Kwon HS, ; Committee of Clinical Practice Guidelines, Korean Diabetes Association; Committee of the Cooperative Studies, Korean Society of Nephrology. Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement. Diabetes Metab J 2020;44:3–10.

33. Nakamura K, Sakurai M, Miura K, et al. HOMA-IR and the risk of hyperuricemia: a prospective study in non-diabetic Japanese men. Diabetes Res Clin Pract 2014;106:154–160.

34. Asma Sakalli A, Küçükerdem HS, Aygün O. What is the relationship between serum uric acid level and insulin resistance?: a case-control study. Medicine (Baltimore) 2023;102:e36732.

35. Zhang Q, Lou S, Meng Z, Ren X. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. Clin Rheumatol 2011;30:777–787.

36. Liu DM, Jiang LD, Gan L, Su Y, Li F. Association between serum uric acid level and body mass index in sex- and age-specific groups in southwestern China. Endocr Pract 2019;25:438–445.

37. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63:3136–3141.

38. Qiu L, Cheng XQ, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health 2013;13:664.

39. Nakanishi N, Yoshida H, Nakamura K, Suzuki K, Tatara K. Predictors for development of hyperuricemia: an 8-year longitudinal study in middle-aged Japanese men. Metabolism 2001;50:621–626.

Article information Continued

(open-access) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1

Baseline characteristics of the study population

Variable	New-onset diabetes (non-awareness) (n = 1,433)	Diabetes duration < 5 y (n = 1,091)	Diabetes duration 5 to < 10 y (n = 704)	Diabetes duration 10 to < 15 y (n = 545)	Diabetes duration ≥ 15 y (n = 802)	p value
Age (y)	56.5 ± 0.4	59.7 ± 0.5	61.4 ± 0.5	63.6 ± 0.6	68.7 ± 0.4	< 0.001
Sex						< 0.001
Male	877 (61.2)	610 (55.9)	370 (52.5)	314 (57.7)	412 (51.4)
Female	556 (38.8)	481 (44.1)	334 (47.5)	231 (42.3)	390 (48.6)
Body mass index (kg/m²)	26.5 ± 0.1	25.8 ± 0.1	25.4 ± 0.2	24.8 ± 0.2	24.5 ± 0.1	< 0.001
Waist circumference (cm)	91.4 ± 0.3	89.8 ± 0.4	89.4 ± 0.4	88.9 ± 0.5	88.6 ± 0.4	< 0.001
Systolic BP (mmHg)	126.8 ± 0.5	122.9 ± 0.5	125.1 ± 0.7	125.2 ± 0.8	128.7 ± 0.8	< 0.001
Diastolic BP (mmHg)	80.1 ± 0.3	75.8 ± 0.4	75.1 ± 0.5	74.2 ± 0.5	70.5 ± 0.4	< 0.001
Fasting glucose (mg/dL)	142.2 ± 1.4	131.6 ± 1.2	141.7 ± 1.9	144.7 ± 2.2	139.8 ± 1.7	< 0.001
HbA1c (%)	7.1 ± 0.1	6.9 ± 0.0	7.3 ± 0.1	7.5 ± 0.1	7.5 ± 0.1	< 0.001
Insulin (μIU/mL)	14.3 ± 0.5	11.4 ± 0.4	11.3 ± 0.6	9.7 ± 0.6	8.6 ± 0.5	< 0.001
HOMA-IR	5.0 ± 0.2	3.7 ± 0.2	3.9 ± 0.2	3.5 ± 0.2	3.0 ± 0.2	< 0.001
Total cholesterol (mg/dL)	202.5 ± 1.3	169.5 ± 1.4	165.5 ± 1.7	163.8 ± 2.1	161.0 ± 1.6	< 0.001
Triglyceride (mg/dL)	200.2 ± 5.7	163.3 ± 4.5	160.0 ± 6.5	148.9 ± 6.1	151.9 ± 4.7	< 0.001
HDL cholesterol (mg/dL)	46.6 ± 0.3	46.2 ± 0.4	45.9 ± 0.5	46.5 ± 0.6	45.7 ± 0.5	< 0.001
LDL cholesterol (mg/dL)	120.6 ± 1.1	94.2 ± 1.2	91.5 ± 1.4	90.1 ± 1.8	87.0 ± 1.3	< 0.001
BUN (mg/dL)	15.5 ± 0.1	16.1 ± 0.2	16.6 ± 0.2	17.1 ± 0.3	18.8 ± 0.3	< 0.001
Creatinine (mg/dL)	0.8 ± 0.0	0.8 ± 0.0	0.9 ± 0.0	0.9 ± 0.0	1.0 ± 0.0	< 0.001
Uric acid (mg/dL)	5.4 ± 0.0	5.0 ± 0.0	4.9 ± 0.0	4.9 ± 0.1	5.1 ± 0.1	< 0.001
Uric acid ≥ 7 mg/dL	192 (13.4)	87 (8.0)	50 (7.1)	44 (8.0)	87 (10.9)	< 0.001
Low-income status	308 (21.5)	271 (24.8)	180 (25.6)	163 (29.9)	324 (40.4)	< 0.001
Smoking status						< 0.001
Non-smoker	675 (47.1)	532 (48.8)	392 (55.7)	259 (47.5)	444 (55.3)
Ex-smoker	400 (27.9)	296 (27.1)	170 (24.2)	216 (39.6)	229 (28.5)
Current smoker	358 (25.0)	263 (24.1)	142 (20.0)	70 (12.9)	129 (16.3)
Alcohol						< 0.001
Non	391 (27.3)	387 (35.5)	284 (40.4)	204 (37.5)	386 (48.1)
Mild	838 (58.5)	589 (54.0)	348 (49.4)	277 (50.8)	357 (44.5)
Heavy	204 (14.3)	115 (10.5)	72 (10.2)	64 (11.7)	59 (7.3)
Regular exercise	555 (38.7)	434 (39.8)	256 (36.4)	194 (35.6)	241 (30.1)	0.006
Hypertension	780 (54.4)	642 (58.8)	427 (60.7)	349 (64.1)	550 (68.6)	< 0.001
Dyslipidemia	539 (37.6)	558 (51.1)	382 (54.2)	264 (48.5)	371 (46.3)	< 0.001
CKD	46 (3.2)	58 (5.3)	56 (7.9)	46 (8.4)	150 (18.7)	< 0.001

Values are presented as mean ± standard deviation or number (%).

BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen; CKD, chronic kidney disease.

	n	Hyperuricemia, n (%)	Model 1	Model 2	Model 3	Model 4
Diabetes duration < 5 y	1,091	87 (8.0)	0.56 (0.42–0.74)	0.57 (0.43–0.77)	0.57 (0.42–0.76)	0.56 (0.41–0.75)
Diabetes duration 5 to < 10 y	704	50 (7.1)	0.49 (0.34–0.71)	0.52 (0.36–0.75)	0.57 (0.39–0.84)	0.55 (0.38–0.82)
Diabetes duration 10 to < 15 y	545	44 (8.0)	0.56 (0.36–0.87)	0.56 (0.35–0.88)	0.62 (0.39–0.97)	0.58 (0.37–0.91)
Diabetes duration ≥ 15 y	802	87 (10.9)	0.79 (0.56–1.11)	0.83 (0.58–1.20)	0.92 (0.63–1.34)	0.89 (0.61–1.29)

Table 3

Association between diabetes duration and hyperuricemia stratified by age, sex, BMI, and CKD

		Model 1		Model 2

		OR (95% CI)	p for interaction	OR (95% CI)	p for interaction
Age < 65 y	New-onset diabetes	1 (reference)	0.396	1 (reference)	0.937

	Diabetes duration < 5 y	0.50 (0.34–0.73)		0.52 (0.34–0.79)

	Diabetes duration 5 to < 10 y	0.37 (0.21–0.64)		0.47 (0.25–0.87)

	Diabetes duration 10 to < 15 y	0.57 (0.29–1.10)		0.61 (0.32–1.17)

	Diabetes duration ≥ 15 y	0.79 (0.40–1.56)		0.69 (0.29–1.63)

Age ≥ 65 y	New-onset diabetes	1 (reference)		1 (reference)

	Diabetes duration < 5 y	0.71 (0.46–1.10)		0.60 (0.38–0.96)

	Diabetes duration 5 to < 10 y	0.71 (0.44–1.17)		0.55 (0.31–0.98)

	Diabetes duration 10 to < 15 y	0.58 (0.33–1.00)		0.47 (0.26–0.83)

	Diabetes duration ≥ 15 y	0.83 (0.54–1.27)		0.62 (0.38–1.02)

Male	New-onset diabetes	1 (reference)	0.457	1 (reference)	0.457

	Diabetes duration < 5 y	0.55 (0.40–0.76)		0.53 (0.38–0.74)

	Diabetes duration 5 to < 10 y	0.49 (0.32–0.76)		0.48 (0.29–0.78)

	Diabetes duration 10 to < 15 y	0.48 (0.28–0.82)		0.47 (0.27–0.80)

	Diabetes duration ≥ 15 y	0.85 (0.57–1.27)		0.71 (0.44–1.14)

Female	New-onset diabetes	1 (reference)		1 (reference)

	Diabetes duration < 5 y	0.75 (0.40–1.39)		0.60 (0.28–1.26)

	Diabetes duration 5 to < 10 y	0.74 (0.37–1.49)		0.57 (0.26–1.24)

	Diabetes duration 10 to < 15 y	1.09 (0.53–2.24)		0.80 (0.38–1.68)

	Diabetes duration ≥ 15 y	1.06 (0.56–2.01)		0.55 (0.23–1.33)

BMI < 25 kg/m²	New-onset diabetes	1 (reference)	0.073	1 (reference)	0.120

	Diabetes duration < 5 y	0.79 (0.49–1.29)		0.70 (0.41–1.21)

	Diabetes duration 5 to < 10 y	0.93 (0.53–1.62)		0.80 (0.43–1.47)

	Diabetes duration 10 to < 15 y	0.67 (0.36–1.25)		0.45 (0.24–0.85)

	Diabetes duration ≥ 15 y	1.15 (0.69–1.91)		0.80 (0.45–1.46)

BMI ≥ 25 kg/m²	New-onset diabetes	1 (reference)		1 (reference)

	Diabetes duration < 5 y	0.49 (0.34–0.71)		0.49 (0.33–0.73)

	Diabetes duration 5 to < 10 y	0.33 (0.21–0.54)		0.33 (0.19–0.58)

	Diabetes duration 10 to < 15 y	0.61 (0.33–1.11)		0.60 (0.31–1.13)

	Diabetes duration ≥ 15 y	0.72 (0.45–1.16)		0.51 (0.29–0.91)

CKD (−)	New-onset diabetes	1 (reference)	0.344	1 (reference)	0.093

	Diabetes duration < 5 y	0.50 (0.36–0.69)		0.52 (0.36–0.74)

	Diabetes duration 5 to < 10 y	0.44 (0.29–0.67)		0.57 (0.36–0.89)

	Diabetes duration 10 to < 15 y	0.42 (0.24–0.74)		0.47 (0.27–0.81)

	Diabetes duration ≥ 15 y	0.58 (0.37–0.90)		0.85 (0.53–1.38)

CKD (+)	New-onset diabetes	1 (reference)		1 (reference)

	Diabetes duration < 5 y	0.46 (0.21–1.02)		0.48 (0.21–1.07)

	Diabetes duration 5 to < 10 y	0.25 (0.10–0.60)		0.25 (0.09–0.68)

	Diabetes duration 10 to < 15 y	0.45 (0.18–1.11)		0.58 (0.24–1.44)

	Diabetes duration ≥ 15 y	0.29 (0.14–0.59)		0.32 (0.15–0.68)

Model 1: non-adjusted. Model 2: adjustment for age, sex, income (Q1), smoking status, alcohol consumption, regular exercise, hypertension, dyslipidemia, and CKD.

BMI, body mass index; CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval.